Serum-based protein biomarkers of bladder cancer: A pre- and post-operative evaluation

Navneeta Bansal, Ashok Kumar Gupta, Ashish Gupta, Satya Narain Sankhwar, Abbas Ali Mahdi

Research output: Contribution to journalArticle

Abstract

Urinary bladder cancer (BC) is the fifth most common cancer worldwide with alarming mortality. Shortcomings of urine cytology and cystoscopy and sparse improvements in the survival rate prompt us to evolve surrogate serum based protein biomarkers to identify BC at an early stage. Previously, we showed that aberrant expression of S100A4, S100A8, S100A9, carbonic anhydrase I (CA I) and Annexin V proteins in pre-operative BC serum compared to healthy controls (HC) (Clin Chim Acta, 2014; 36: 97-103). Here we further evaluate and validate these findings with follow-up post-operative BC patients. This study was conducted on 160 sera samples comprising healthy controls (HC, n = 52), pre-operative (n = 55) and post-operative (n = 53) BC patients. Enzyme-linked immunosorbent assay (ELISA) was used to appraise the aberrantly expressed proteins. ELISA results revealed that the expression levels of S100A8, S100A9, S100A4, and CA I were gradually and significantly reduced; concomitantly, Annexin V was progressively and significantly increased in post-operative compared to pre-operative BC sera samples. Serum protein biomarkers appear to be an encouraging and least-invasive approach for BC identification and prognosticating patient outcomes.

Original languageEnglish (US)
Pages (from-to)22-25
Number of pages4
JournalJournal of Pharmaceutical and Biomedical Analysis
Volume124
DOIs
StatePublished - May 30 2016
Externally publishedYes

Fingerprint

Biomarkers
Carbonic Anhydrase I
Urinary Bladder Neoplasms
Blood Proteins
Immunosorbents
Annexin A5
Assays
Cytology
Proteins
Enzymes
Carbonic Anhydrase V
Serum
Enzyme-Linked Immunosorbent Assay
Cystoscopy
Cell Biology
Survival Rate
Urine
Mortality
Neoplasms

Keywords

  • Enzyme-linked immunosorbent assay
  • Serum proteomics
  • Urinary bladder cancer

ASJC Scopus subject areas

  • Analytical Chemistry
  • Drug Discovery
  • Pharmaceutical Science
  • Spectroscopy
  • Clinical Biochemistry

Cite this

Serum-based protein biomarkers of bladder cancer : A pre- and post-operative evaluation. / Bansal, Navneeta; Gupta, Ashok Kumar; Gupta, Ashish; Sankhwar, Satya Narain; Mahdi, Abbas Ali.

In: Journal of Pharmaceutical and Biomedical Analysis, Vol. 124, 30.05.2016, p. 22-25.

Research output: Contribution to journalArticle

Bansal, Navneeta ; Gupta, Ashok Kumar ; Gupta, Ashish ; Sankhwar, Satya Narain ; Mahdi, Abbas Ali. / Serum-based protein biomarkers of bladder cancer : A pre- and post-operative evaluation. In: Journal of Pharmaceutical and Biomedical Analysis. 2016 ; Vol. 124. pp. 22-25.
@article{c31026d5b3fc48e0a3a2baa4dd99c803,
title = "Serum-based protein biomarkers of bladder cancer: A pre- and post-operative evaluation",
abstract = "Urinary bladder cancer (BC) is the fifth most common cancer worldwide with alarming mortality. Shortcomings of urine cytology and cystoscopy and sparse improvements in the survival rate prompt us to evolve surrogate serum based protein biomarkers to identify BC at an early stage. Previously, we showed that aberrant expression of S100A4, S100A8, S100A9, carbonic anhydrase I (CA I) and Annexin V proteins in pre-operative BC serum compared to healthy controls (HC) (Clin Chim Acta, 2014; 36: 97-103). Here we further evaluate and validate these findings with follow-up post-operative BC patients. This study was conducted on 160 sera samples comprising healthy controls (HC, n = 52), pre-operative (n = 55) and post-operative (n = 53) BC patients. Enzyme-linked immunosorbent assay (ELISA) was used to appraise the aberrantly expressed proteins. ELISA results revealed that the expression levels of S100A8, S100A9, S100A4, and CA I were gradually and significantly reduced; concomitantly, Annexin V was progressively and significantly increased in post-operative compared to pre-operative BC sera samples. Serum protein biomarkers appear to be an encouraging and least-invasive approach for BC identification and prognosticating patient outcomes.",
keywords = "Enzyme-linked immunosorbent assay, Serum proteomics, Urinary bladder cancer",
author = "Navneeta Bansal and Gupta, {Ashok Kumar} and Ashish Gupta and Sankhwar, {Satya Narain} and Mahdi, {Abbas Ali}",
year = "2016",
month = "5",
day = "30",
doi = "10.1016/j.jpba.2016.02.026",
language = "English (US)",
volume = "124",
pages = "22--25",
journal = "Journal of Pharmaceutical and Biomedical Analysis",
issn = "0731-7085",
publisher = "Elsevier",

}

TY - JOUR

T1 - Serum-based protein biomarkers of bladder cancer

T2 - A pre- and post-operative evaluation

AU - Bansal, Navneeta

AU - Gupta, Ashok Kumar

AU - Gupta, Ashish

AU - Sankhwar, Satya Narain

AU - Mahdi, Abbas Ali

PY - 2016/5/30

Y1 - 2016/5/30

N2 - Urinary bladder cancer (BC) is the fifth most common cancer worldwide with alarming mortality. Shortcomings of urine cytology and cystoscopy and sparse improvements in the survival rate prompt us to evolve surrogate serum based protein biomarkers to identify BC at an early stage. Previously, we showed that aberrant expression of S100A4, S100A8, S100A9, carbonic anhydrase I (CA I) and Annexin V proteins in pre-operative BC serum compared to healthy controls (HC) (Clin Chim Acta, 2014; 36: 97-103). Here we further evaluate and validate these findings with follow-up post-operative BC patients. This study was conducted on 160 sera samples comprising healthy controls (HC, n = 52), pre-operative (n = 55) and post-operative (n = 53) BC patients. Enzyme-linked immunosorbent assay (ELISA) was used to appraise the aberrantly expressed proteins. ELISA results revealed that the expression levels of S100A8, S100A9, S100A4, and CA I were gradually and significantly reduced; concomitantly, Annexin V was progressively and significantly increased in post-operative compared to pre-operative BC sera samples. Serum protein biomarkers appear to be an encouraging and least-invasive approach for BC identification and prognosticating patient outcomes.

AB - Urinary bladder cancer (BC) is the fifth most common cancer worldwide with alarming mortality. Shortcomings of urine cytology and cystoscopy and sparse improvements in the survival rate prompt us to evolve surrogate serum based protein biomarkers to identify BC at an early stage. Previously, we showed that aberrant expression of S100A4, S100A8, S100A9, carbonic anhydrase I (CA I) and Annexin V proteins in pre-operative BC serum compared to healthy controls (HC) (Clin Chim Acta, 2014; 36: 97-103). Here we further evaluate and validate these findings with follow-up post-operative BC patients. This study was conducted on 160 sera samples comprising healthy controls (HC, n = 52), pre-operative (n = 55) and post-operative (n = 53) BC patients. Enzyme-linked immunosorbent assay (ELISA) was used to appraise the aberrantly expressed proteins. ELISA results revealed that the expression levels of S100A8, S100A9, S100A4, and CA I were gradually and significantly reduced; concomitantly, Annexin V was progressively and significantly increased in post-operative compared to pre-operative BC sera samples. Serum protein biomarkers appear to be an encouraging and least-invasive approach for BC identification and prognosticating patient outcomes.

KW - Enzyme-linked immunosorbent assay

KW - Serum proteomics

KW - Urinary bladder cancer

UR - http://www.scopus.com/inward/record.url?scp=84959105824&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959105824&partnerID=8YFLogxK

U2 - 10.1016/j.jpba.2016.02.026

DO - 10.1016/j.jpba.2016.02.026

M3 - Article

C2 - 26922578

AN - SCOPUS:84959105824

VL - 124

SP - 22

EP - 25

JO - Journal of Pharmaceutical and Biomedical Analysis

JF - Journal of Pharmaceutical and Biomedical Analysis

SN - 0731-7085

ER -